<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258553</url>
  </required_header>
  <id_info>
    <org_study_id>19/09/2018-15-4</org_study_id>
    <nct_id>NCT04258553</nct_id>
  </id_info>
  <brief_title>Thiol Disulfide Balance in Cervix Cancer</brief_title>
  <official_title>Evaluation of Thiol Disulfide Balance in Cervix Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to evaluate thiol‑disulfide balance in cervix cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date various oxidative stress parameters were studied in patients with cervix cancer,
      however dynamic thiol disulfide hemostasis has not been previously investigated.

      The thiol-disulfide balance in the circulation will be measured by the automated system
      created by Erel &amp; Neselioglu (1).

      References

      1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin
      Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">February 4, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum native thiol level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum native thiol level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum disulphide level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum disulphide level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum total thiol level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum total thiol level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the disulphide/native thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>the disulphide/native thiol ratio X (100 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disulphide/total thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>disulphide/total thiol ratio X (100 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>native thiol/total thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>native thiol/total thiol ratio X (100 )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total oxidant capacity (TOC)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>TOC in mmol H2O2 equivalent/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total antioxidant capacity (TAC)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>TAC in mmol trolox equivalent/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress index (OSI)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>OSI in mmol trolox/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischaemia-modified albumin</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>ischaemia-modified albumin in IU/mL</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Cervix Cancer</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Cervix cancer</arm_group_label>
    <description>Cervix cancer n=62</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy volunteers n=61</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Disulphide(μmol/L)</intervention_name>
    <description>Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry</description>
    <arm_group_label>Cervix cancer</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Native thiol (μmol/L)</other_name>
    <other_name>Total thiol (μmol/L)</other_name>
    <other_name>Native thiol/totalthiol(%)</other_name>
    <other_name>Disulfide/native thiol(%)</other_name>
    <other_name>Disulfide/total thiol(%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Total Oxidant Capacity(μmolH2O2Equiv/L)</intervention_name>
    <description>Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry</description>
    <arm_group_label>Cervix cancer</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Total Antioxidant Capacity(mmolTroloxEquiv/L)</other_name>
    <other_name>Oxidative stress Index (Arbitrary Unite)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ischemia Modified Albumin(IU/mL)</intervention_name>
    <description>The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).</description>
    <arm_group_label>Cervix cancer</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum blood samples for each participant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The preoperative diagnosis of cervix cancer was made histopathologically by cervical
        biopsy. An experienced pathologist performed pathological analysis according to the
        surgical staging scheme of the International Federation of Gynaecology and Obstetrics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Histopathologically confirmed diagnosis of cervix cancer

        Exclusion Criteria:

          -  pulmonary disease

          -  pulmonary hypertension

          -  cardiac dysfunction

          -  renal dysfunction

          -  liver disease

          -  chronic ischemia

          -  systemic inflammation

          -  concomitant malignancy

          -  patients who use vitamin A,C or E (antioxidant vitamins)

          -  patients who use smoke

          -  patients who use drink alcohol

          -  patients who use addictive for any drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>cervix cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak Sezgin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mugla Sıtkı Kocman University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mugla Sıtkı Kocman University Faculty of Medicine</name>
      <address>
        <city>Mugla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Burak Sezgin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>thiol disulfide hemostasis</keyword>
  <keyword>screening</keyword>
  <keyword>early diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

